IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice
This study has been completed.
Sponsor:
Pfizer
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00855738
First received: March 3, 2009
Last updated: November 23, 2010
Last verified: November 2010
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Assessment of the efficacy under daily clinical conditions of the new antiepileptic drugs (AEDs) gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine and topiramate, used as first-choice combination therapy (bitherapy) in patients with focal epilepsy.
| Condition | Intervention | Phase |
|---|---|---|
| Focal Epilepsy | Drug: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Liceo Study: A Prospective, Observational Study On The Effectiveness Of New Antiepileptic Drugs As First Bitherapy In The Daily Clinical Practice |
Resource links provided by NLM:
Genetics Home Reference related topics:
autosomal dominant partial epilepsy with auditory features
pyridoxal 5'-phosphate-dependent epilepsy
MedlinePlus related topics:
Epilepsy
Drug Information available for:
Gabapentin
Zonisamide
Lamotrigine
Topiramate
Levetiracetam
Tiagabine
Tiagabine hydrochloride
Pregabalin
Gabapentin enacarbil
U.S. FDA Resources
Further study details as provided by Pfizer:
Primary Outcome Measures:
- Percent of Participants Classified as Responders [ Time Frame: Baseline, Month 3, Month 6 (last 3 months of treatment) ]Responder = decrease in number of seizures by >=50 percent (%) during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the number of seizures that occurred during the 3 months before the baseline visit (baseline).
Secondary Outcome Measures:
- Percent of Participants With Reduction in Number of Seizures >=25% and >=75% During the Last 3 Months of Treatment [ Time Frame: Baseline, Month 3, Month 6 (last 3 months of treatment) ]Percent of participants with reduction in number of seizures >=25% and >=75% during the last 3 months of treatment before discontinuation (assessed at Month 3 and Month 6) versus the 3 month period before the baseline visit.
- Percent of Seizure-free Participants During the Last 3 Months Before Discontinuation [ Time Frame: Baseline, Month 3, Month 6 (last 3 months of treatment) ]
- Percent Change From Baseline in the Median Number of Seizures During the Last 3 Months of Treatment [ Time Frame: Baseline, Month 3, Month 6 (last 3 months of treatment) ]
- Percent of Days Without Crisis During the Study [ Time Frame: Baseline through Month 6 (or end of treatment) ]Crisis was defined as the total number of seizures during the study, the seizures at month 3 plus the seizures at month 6. The percent of days without crisis is number of days of study (date of last visit minus date of baseline visit) without crisis divided by number of days of study, multiplied by 100.
- Time to First Seizure [ Time Frame: Baseline to Month 6 (or end of treatment) ]Number of days to first seizure after baseline.
- Percent of Participants Who Continued on Study Medication to Month 6 [ Time Frame: Baseline to Month 6 ]Retention rate: percent of participants who continued on study medication throughout the 6 Month period after inclusion in the study.
- Time to Discontinuation Due to Lack of Efficacy [ Time Frame: Baseline, Month 3, Month 6 ]
- Time to Discontinuation Due to Safety, Tolerability, or Treatment Compliance [ Time Frame: Baseline, Month 3, Month 6 ]
- Time to Discontinuation Due to Other Reasons [ Time Frame: Baseline, Month 3, Month 6 ]
- Treatment Satisfaction Evaluated by Patient Global Impression of Change Visual Analog Scale (VAS) [ Time Frame: Baseline, Month 3, Month 6 ]Patient Global Impression of Change VAS: subject rated instrument to measure subject's change in overall status; range from 0 (much better) to 10 (much worse).
- Percent of Participants Reaching Monotherapy [ Time Frame: Baseline through Month 6 (or end of study) ]Percent of participants who started on more than one treatment (bitherapy) and reached monotherapy by end of study.
- Percent of Participants That Reduced, Maintained and Increased Their Doses of New Antiepileptic Drugs (AED) [ Time Frame: Baseline to Month 6 (or end of treatment) ]
- Percent of Participants That Reduced, Maintained and Increased the Doses of the Initial Treatment Administered in Monotherapy [ Time Frame: Baseline through Month 6 (or end of treatment) ]
- Change From Baseline to Month 6 in the Hospital Anxiety and Depression Scale (HADS) [ Time Frame: Baseline to Month 6 ]HADS: subject rated questionnaire with 2 subscales. HADS-A assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.
- Change From Baseline to Month 6 in Quality of Life 10 Domains (QOLIE-10) [ Time Frame: Baseline to Month 6 ]QOLIE-10: 10-item questionnaire evaluates health-related quality of life in individuals with epliepsy. Comprised of 7 components: seizure worry, overall quality of life, emotional well-being, energy, cognitive functioning, medication effects (physical and mental effects), and social function (work, driving, social function). Total score rated 0 to 100; higher score = higher quality of life.
- Change From Baseline to Months 3 and 6 in Health Condition: Euro Quality of Life Scale (EQ-5D) Visual Analog Scale (VAS) [ Time Frame: Baseline, Month 3, Month 6 ]Assessment of the health condition of the subjects using the EQ-5D VAS: subject rated questionnaire to assess health-related quality of life in terms of a single index value. Using the VAS subjects rated current health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicate a better health state.
- Change in Sleep Disturbances From Baseline to Month 6: Medical Outcomes Study Sleep Scale (MOS-SS) [ Time Frame: Baseline to Month 6 ]Subject rated instrument to assess key constructs of sleep; assesses sleep quality and quantity. Consists of a 6-item and 9-item overall sleep problems index measuring time to fall asleep and sleep duration in past 4 weeks; 5 subscales rated 1 (all the time) to 6 (none of the time): sleep disturbance, snoring, awaken short of breath, somnolence, and adequacy. Transformed scores range = 0 to 100; higher score indicates greater intensity of attribute. Two additional subscales = sleep quantity (range 0-24 hours) and optimal sleep (number of participants with optimal sleep 7-8 hours per night).
- Percent of Participants Indicating Optimal Sleep on the Optimal Sleep Subscale: Medical Outcomes Study Sleep Scale (MOS-SS) [ Time Frame: Baseline, Month 6 ]MOS-SS: subject rated instrument used to assess the key constructs of sleep; assesses sleep quantity and quality and is comprised of 12 items yielding 7 subscale scores and 2 composite index scores. Optimal sleep subscale is derived from sleep quantity average hours of sleep over the past 4 weeks; percent of participants with response YES (optimal) if sleep quantilty was 7-8 hours of sleep per night.
- Change From Baseline to Month 6 in Visits to a Specialist or the Emergency Room Because of Epilepsy [ Time Frame: Baseline to Month 6 ]Numerical assessment of change in the number of visits to a specialist or the emergency room because of epilepsy needed during the study.
- Change From Baseline to Month 6 in Total Number of Days Hospitalized Because of Epilepsy [ Time Frame: Baseline to Month 6 ]Numerical assessment of change in total number of days hospitalized because of epilepsy during the study.
- Percent of Participants With Cessation of Occupation, Requirement of Caregiver, or Admission to Intensive Care Unit [ Time Frame: Month 6 ]Percent of participants with cessation of usual occupation, requirement of an informal caregiver, and who required admission to the intensive care unit (ICU).
| Enrollment: | 111 |
| Study Start Date: | May 2007 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| 1.0 |
Drug: Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide
Other Name: Neurontin, Lamictal, Lyrica, Keppra, Topamax, Gabatril, Episen, Zonegran
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Aged 18 years or older.
- Diagnosis of focal epilepsy.
- Previous failure of one or more AEDs used in monotherapy.
- Background treatment with an antiepileptic drug.
- The investigator has considered that the patient must start treatment with some of the seven new AEDs in combination therapy: lamotrigine, levetiracetam, gabapentin, oxcarbazepine, pregabalin, tiagabine and/or topiramate.
- History of seizures in the patient in the past 3 months.
- The patient or legal guardian must be able to understand the characteristics of the study and fill in the seizure diaries.
- Written informed consent.
Exclusion Criteria:
- Inability to comply with the study requirements.
- Diagnosis of generalized epilepsy or inability to establish if focal or generalized.
- Presence of serious or uncontrolled systemic disease, serious psychiatric disease or progressive neurological disease.
- History of alcoholism, drug addiction, or abuse of medicines in the past two years.
- Psychogenic seizures in the two years prior to inclusion in the study.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00855738
Please refer to this study by its ClinicalTrials.gov identifier: NCT00855738
Sponsors and Collaborators
Pfizer
Investigators
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
Additional Information:
| Responsible Party: | Director, Clinical Trial Disclosure Group, Pfizer, Inc. |
| ClinicalTrials.gov Identifier: | NCT00855738 History of Changes |
| Other Study ID Numbers: |
A0081144 LICEO STUDY |
| Study First Received: | March 3, 2009 |
| Results First Received: | June 23, 2010 |
| Last Updated: | November 23, 2010 |
Keywords provided by Pfizer:
|
epilepsy antiepileptic biotherapy |
Additional relevant MeSH terms:
|
Epilepsy Epilepsies, Partial Brain Diseases Central Nervous System Diseases Nervous System Diseases Pregabalin Gabapentin Topiramate Etiracetam Lamotrigine Zonisamide Tiagabine Anticonvulsants Analgesics Sensory System Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Antiparkinson Agents Anti-Dyskinesia Agents Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Antimanic Agents |
ClinicalTrials.gov processed this record on July 26, 2017